Cancer Cell
Volume 19, Issue 1, 18 January 2011, Pages 17-30
Journal home page for Cancer Cell

Article
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

https://doi.org/10.1016/j.ccr.2010.12.014Get rights and content
Under an Elsevier user license
open archive

Summary

IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.

Highlights

► 2-HG is a weak competitive inhibitor of α-KG-dependent dioxygenases ► 2-HG inhibits histone demethylases and TET 5-metyhlcytsine hydroxylases ► Mutant IDH1 and 2-HG inhibits multiple α-KG-dependent dioxygenases ► Mutant IDH1 and 2-HG alters genome-wide histone and DNA methylation

Cited by (0)

12

These authors contributed equally to this work